Analysts Expect Clearside Biomedical, Inc. (NASDAQ:CLSD) Will Announce Quarterly Sales of $9.06 Million

Equities research analysts predict that Clearside Biomedical, Inc. (NASDAQ:CLSDGet Rating) will report $9.06 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Clearside Biomedical’s earnings. The highest sales estimate is $25.69 million and the lowest is $500,000.00. Clearside Biomedical posted sales of $780,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 1,061.5%. The firm is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Clearside Biomedical will report full year sales of $15.23 million for the current fiscal year, with estimates ranging from $120,000.00 to $55.25 million. For the next year, analysts forecast that the business will report sales of $6.50 million, with estimates ranging from $610,000.00 to $10.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSDGet Rating) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.10). Clearside Biomedical had a net margin of 0.28% and a return on equity of 0.31%. During the same period in the prior year, the firm earned ($0.13) EPS.

A number of research firms have recently weighed in on CLSD. TheStreet lowered shares of Clearside Biomedical from a “c” rating to a “d+” rating in a report on Wednesday, May 11th. StockNews.com began coverage on shares of Clearside Biomedical in a report on Thursday, March 31st. They issued a “hold” rating for the company. Wedbush restated an “outperform” rating and issued a $9.00 price objective on shares of Clearside Biomedical in a report on Friday, March 11th. Zacks Investment Research lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Monday, May 2nd. Finally, JMP Securities lowered their price objective on shares of Clearside Biomedical from $11.00 to $10.00 and set a “market outperform” rating for the company in a report on Friday, March 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Clearside Biomedical has an average rating of “Buy” and a consensus target price of $9.25.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Investment Company LLC increased its position in shares of Clearside Biomedical by 19.7% during the third quarter. Ameritas Investment Company LLC now owns 60,810 shares of the company’s stock valued at $365,000 after acquiring an additional 10,000 shares in the last quarter. Jump Financial LLC bought a new stake in Clearside Biomedical in the 3rd quarter worth approximately $229,000. Assenagon Asset Management S.A. grew its position in Clearside Biomedical by 8,559.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,634,412 shares of the company’s stock worth $4,495,000 after purchasing an additional 1,615,538 shares during the period. Trexquant Investment LP bought a new stake in Clearside Biomedical in the 3rd quarter worth approximately $263,000. Finally, Cubist Systematic Strategies LLC grew its position in Clearside Biomedical by 200.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 79,967 shares of the company’s stock worth $480,000 after purchasing an additional 53,311 shares during the period. 44.71% of the stock is owned by institutional investors.

Shares of NASDAQ:CLSD remained flat at $$1.34 on Friday. The stock had a trading volume of 212,027 shares, compared to its average volume of 753,418. The business has a 50 day simple moving average of $1.85 and a 200-day simple moving average of $2.30. The stock has a market capitalization of $80.60 million, a PE ratio of -134.00 and a beta of 2.15. Clearside Biomedical has a 52-week low of $1.27 and a 52-week high of $7.73.

Clearside Biomedical Company Profile (Get Rating)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

See Also

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.